Bristol lung-cancer setback puts rival Merck drug in driver seat

Bristol lung-cancer setback puts rival Merck drug in driver seat
 

New data is likely to prompt doctors to abandon Bristol-Myers Squibb's (BMY.N) immunotherapy Opdivo in favor of Merck & Co's (MRK.N) rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday. The results of a closely watched clinical trial sent Bristol's shares plunging 10 percent. The data, presented at a medical meeting on Sunday, showed that lung cancer patients fared worse on Opdivo than those on chemotherapy. Merck shares rose nearly 2 percent on strong benefits shown by Keytruda in a similar late-stage lung cancer study.
Both trials tested the... read more

 
10 October 2016 in Business, Views: 46
Source: Reuters
Share:
  •  




    News Widget for Webmasters


    Realtime News

     

    «
    »
    Mo Tu We Th Fr Sa Su
            1 2 3
    4 5 6 7 8 9 10
    11 12 13 14 15 16 17
    18 19 20 21 22 23 24
    25 26 27 28 29 30 31